Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3377-3386

  Akli, Said ^a   Van Pelt, Carolyn S ^b   Bui, Tuyen ^a   Meijer, Laurent ^d   Keyomarsi, Khandan ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; ISOPROTEIN; MERIOLIN 5; PROTEIN P53; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; CANCER CELL CULTURE; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE SILENCING; HETEROZYGOTE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; FEMALE; GENE SILENCING; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PURINES;

EID: 79955490608     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4086     Document Type: Article

References (47)

1. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
2. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86. (Pubitemid 40638089)
3. Caldon CE, Sutherland RL, Musgrove EA. Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer. Cell Cycle 2010;9:1918-28.
4. Caldon CE, Musgrove EA. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 2010; 5:2.
5. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21: 6254-69. (Pubitemid 34263525)
6. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208. (Pubitemid 38581423)
7. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70:5085-95.
8. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70:5074-84.
9. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75. (Pubitemid 35315837)
10. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007;67:7212-22. (Pubitemid 47206549)
11. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003;2:461-6.
12. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, et al. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16:1179-90.
13. Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000;14:2298-313.
14. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-40.
15. Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 2002;3:339-50.
16. Grimison B, Liu J, Lewellyn AL, Maller JL. Metaphase arrest by cyclin E-Cdk2 requires the spindle-checkpoint kinase Mps1. Curr Biol 2006;16:1968-73. (Pubitemid 44486762)
17. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 1999;19:4843-54. (Pubitemid 29289523)
18. Mazumder S, Plesca D, Almasan A. A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell Cycle 2007;6:1437-42.
19. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell 2003;114:431-43. (Pubitemid 37100992)
20. Parisi T, Beck AR, Rougier N, McNeil T, Lucian L, Werb Z, et al. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J 2003;22:4794-803. (Pubitemid 37162915)
21. Geng Y, Lee YM, Welcker M, Swanger J, Zagozdzon A, Winer JD, et al. Kinase-independent function of cyclin E. Mol Cell 2007;25:127-39. (Pubitemid 46049064)
22. Berger C, Pallavi SK, Prasad M, Shashidhara LS, Technau GM. A critical role for cyclin E in cell fate determination in the central nervous system of Drosophila melanogaster. Nat Cell Biol 2005;7:56-62. (Pubitemid 40123383)
23. Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science 2004;306: 885-8. (Pubitemid 39447000)
24. Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R, et al. Cyclindependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31. (Pubitemid 37048592)
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
26. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-402. (Pubitemid 28515393)
27. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6. (Pubitemid 23053961)
28. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50.
29. Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem 1997;272:29207-11. (Pubitemid 27498212)
30. Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007;67:8325-34. (Pubitemid 47395171)
31. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36. (Pubitemid 27060443)
32. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005;280:15148-57. (Pubitemid 40562869)
33. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
34. Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clément M, Valette A, et al. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/ meriolin complex. J Med Chem 2008;51:737-51.
35. Berthet C, Rodriguez-Galan MC, Hodge DL, Gooya J, Pascal V, Young HA, et al. Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2. Mol Cell Biol 2007;27:5079-89. (Pubitemid 47068283)
36. Vandenbosch R, Borgs L, Beukelaers P, Foidart A, Nguyen L, Moonen G, et al. CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle 2007;6:3065-9.
37. Jablonska B, Aguirre A, Vandenbosch R, Belachew S, Berthet C, Kaldis P, et al. Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. J Cell Biol 2007;179:1231-45. (Pubitemid 350277741)
38. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005;7:831-6. (Pubitemid 41079056)
39. Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I. A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol 2010;33:393-7.
40. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37. (Pubitemid 46094635)
41. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004;22:315-22. (Pubitemid 39012571)
42. Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:249-53. (Pubitemid 41019113)
43. El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-10.
44. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13:5841-6.
45. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-41. (Pubitemid 41170323)
46. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404. (Pubitemid 46105932)
47. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113:2637-45.